UK markets closed

Abingdon Health Plc (ABDX.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
90.00-1.50 (-1.64%)
At close: 4:26PM GMT
Full screen
Previous close91.50
Open90.15
Bid85.00 x N/A
Ask95.00 x N/A
Day's range87.02 - 92.45
52-week range80.25 - 136.65
Volume101,019
Avg. volume313,549
Market cap86.129M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • AbC-19™ Rapid Test Available for Purchase by Healthcare Professionals
    Business Wire

    AbC-19™ Rapid Test Available for Purchase by Healthcare Professionals

    Abingdon Health plc ("the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, announces that the AbC-19™ Rapid Test for the detection of SARS-CoV-2 antibodies is now available for purchase by healthcare professionals on the Abingdon Health website.

  • Globe Newswire

    Abingdon Health signs collaboration and co-marketing agreement with Abcam

    Abingdon Health signs collaboration and co-marketing agreement with Abcam York, and Cambridge U.K. 09 February 2021: Abingdon Health (AIM:ABDX) (“Abingdon” or “the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, has signed a collaboration and co-marketing agreement with Abcam plc (NASDAQ:ABCM; AIM:ABC) (“Abcam”), a global leader in the supply of life science research tools and reagents. The Parties intend to establish a collaborative strategic relationship to enable them to identify and maximise opportunities for the provision of each Party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services. Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services, for the Company’s lateral flow assays. Custom conjugation reagents will include a combination of an affinity binding reagent such as an antibody, and signal reagents such as the colloidal gold which provides the colour output in a lateral flow assay. Securing a reliable source for custom conjugation reagents ensures reliable supply chains of critical reagents for customers of Abingdon by providing access to the reagents, colloidal gold and specialist conjugation services of Abcam. Chris Yates, Abingdon’s Chief Executive Officer, commented: “Abcam is a global leader in the supply of biochemical reagents, a critical component required in the manufacturing of our lateral flow tests and we are delighted to have signed this agreement with them. At a time when there is a shortage of such reagents in the market, this agreement secures a key supply chain for us. This will also ensure our partners and customers will have certainty of delivery when they come to us to manufacture their tests. We also look forward to working with Abcam to identify and service their customers’ lateral flow contract development and manufacturing requirements.” Mennah Moustafa, Abcam’s VP of Business Development, commented “We are excited to be collaborating with Abingdon Health to provide critical components for their lateral flow tests. As Abingdon’s source of key reagents and custom conjugation, we believe the combination of our global reach and complementary capabilities and expertise will enable more assay developers to access this core rapid diagnostic technology. We are looking forward to working together to enhance access and help secure long-term critical reagent supply to customers of Abingdon’s contract development and manufacturing services.” Enquiries: Abingdon Health plc Chris YatesChief Executive OfficerVia ConsiliumMelanie RossChief Financial Officer Chris HandNon-Executive Chairman N+1 SingerSole Broker and Nominated AdviserShaun Dobson, Peter Steel, Tel: +44 (0) 20 7496 3000Alex Bond (Corporate Finance) Tom Salvesen (Corporate Broking) ConsiliumFinancial PRTel: +44 (0) 203 709 5700Matthew Nealabingdonhealth@consilium-comms.comMary-Jane Elliott Lindsey Neville About Abingdon HealthAbingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England. https://www.abingdonhealth.com/ About Abcam plc As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading antibody expertise. By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products. With 13 sites globally, many of Abcam's 1,500-strong team are located in the world's leading life science research hubs, complementing a global network of services and support. To find out more, please visit www.abcam.com and www.abcamplc.com. At Abcam Media: Dr Lynne Trowbridge, VP External Communications T: +44 (0)7815 167026 E: Lynne.Trowbridge@abcam.com

  • Globe Newswire

    Outsourcing vs Inhouse Resourcing For Lateral Flow Test Manufacturing

    Outsourcing vs Inhouse Resourcing For Lateral Flow Test Manufacturing New guide published by leading rapid test developer and manufacturer advises on moving faster, containing risks, and embracing opportunities through outsourced manufacturing York, U.K. 03 February 2021: Abingdon Health (“the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, has today published a new guide highlighting the benefits to businesses of outsourcing lateral flow test manufacturing services. These potential benefits include: Reduced costs and increased profitsWider business benefits, including allowing customers to focus on core capabilitiesEfficiency gains, through people, processes, and technologyEnsuring that quality and compliance regulations are metIncreased competitiveness and market shareThe value that outsourcing partners can provide beyond the life cycle of the product portfolio Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, and is the partner of choice for a growing global customer base. The Company takes projects from initial concept through to routine and large-scale manufacturing. A full service is available to customers at the early stages of their lateral flow project looking for a partner to take a rapid test from concept through to market launch. Abingdon Health offers a full suite of lateral flow services from development and manufacture through to Smartphone reader customisation and regulatory support. The guide can be accessed on the Abingdon Health website here and to find out more about how Abingdon Health can help with your outsourcing requirements, please contact us at: info@abingdonhealth.com. Leigh Thomas, SVP Director of Global Sales of Abingdon Health, commented: “There are many innovative companies working in the lateral flow space who find that in-house manufacturing may be unsuitable or unsustainable for numerous reasons, such as costs, logistics, or time constraints. Outsourcing the manufacturing of these tests can be the strategic solution for many developers, allowing them to focus innovation, rather than the logistics of production. We are happy to discuss our own outsourcing offering further with anyone interested in learning more.” For more information please contact: Abingdon Health +44 (0) 1904 406082 Leigh Thomas, SVP Director of Global Sales of Abingdon Health info@abingdonhealth.com Consilium Strategic Communications +44 (0) 203 709 5700 Matthew Neal abingdonhealth@consilium-comms.com Mary-Jane ElliottLindsey Neville About Abingdon HealthAbingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England. https://www.abingdonhealth.com/ AbC-19TM Rapid TestThe Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.